vs

Side-by-side financial comparison of FRP HOLDINGS, INC. (FRPH) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $10.9M, roughly 1.8× FRP HOLDINGS, INC.). FRP HOLDINGS, INC. runs the higher net margin — 1.3% vs -177.4%, a 178.7% gap on every dollar of revenue. On growth, FRP HOLDINGS, INC. posted the faster year-over-year revenue change (3.6% vs -11.5%). FRP HOLDINGS, INC. produced more free cash flow last quarter ($-21.5M vs $-23.1M). Over the past eight quarters, FRP HOLDINGS, INC.'s revenue compounded faster (3.8% CAGR vs -12.2%).

FRP Advisory is a business advisory firm based in the United Kingdom, providing restructuring, corporate finance, debt advisory, forensic accounting and financial advisory and is one of the UK’s largest specialists in the area of corporate restructuring.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FRPH vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.8× larger
LAB
$19.6M
$10.9M
FRPH
Growing faster (revenue YoY)
FRPH
FRPH
+15.1% gap
FRPH
3.6%
-11.5%
LAB
Higher net margin
FRPH
FRPH
178.7% more per $
FRPH
1.3%
-177.4%
LAB
More free cash flow
FRPH
FRPH
$1.6M more FCF
FRPH
$-21.5M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FRPH
FRPH
Annualised
FRPH
3.8%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FRPH
FRPH
LAB
LAB
Revenue
$10.9M
$19.6M
Net Profit
$139.0K
$-34.7M
Gross Margin
48.5%
Operating Margin
15.4%
-168.5%
Net Margin
1.3%
-177.4%
Revenue YoY
3.6%
-11.5%
Net Profit YoY
-91.8%
-28.8%
EPS (diluted)
$0.03
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRPH
FRPH
LAB
LAB
Q4 25
$10.9M
Q3 25
$10.8M
$19.6M
Q2 25
$10.8M
$21.8M
Q1 25
$10.3M
$40.8M
Q4 24
$10.5M
Q3 24
$10.6M
$22.1M
Q2 24
$10.5M
$22.5M
Q1 24
$10.1M
$45.5M
Net Profit
FRPH
FRPH
LAB
LAB
Q4 25
$139.0K
Q3 25
$662.0K
$-34.7M
Q2 25
$578.0K
$-33.5M
Q1 25
$1.7M
$-26.0M
Q4 24
$1.7M
Q3 24
$1.4M
$-26.9M
Q2 24
$2.0M
$-45.7M
Q1 24
$1.3M
$-32.2M
Gross Margin
FRPH
FRPH
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
FRPH
FRPH
LAB
LAB
Q4 25
15.4%
Q3 25
12.6%
-168.5%
Q2 25
15.3%
-118.1%
Q1 25
22.6%
-80.8%
Q4 24
27.7%
Q3 24
29.0%
-120.9%
Q2 24
26.9%
-134.5%
Q1 24
28.4%
-132.2%
Net Margin
FRPH
FRPH
LAB
LAB
Q4 25
1.3%
Q3 25
6.1%
-177.4%
Q2 25
5.3%
-153.7%
Q1 25
16.6%
-63.8%
Q4 24
16.0%
Q3 24
12.8%
-122.0%
Q2 24
19.5%
-203.3%
Q1 24
12.8%
-70.6%
EPS (diluted)
FRPH
FRPH
LAB
LAB
Q4 25
$0.03
Q3 25
$0.03
$-0.09
Q2 25
$0.03
$-0.09
Q1 25
$0.09
$-0.07
Q4 24
$0.09
Q3 24
$0.07
$-0.07
Q2 24
$0.11
$-0.12
Q1 24
$0.07
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRPH
FRPH
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
$192.6M
Stockholders' EquityBook value
$428.5M
$399.7M
Total Assets
$735.1M
$539.6M
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRPH
FRPH
LAB
LAB
Q4 25
Q3 25
$134.9M
$129.4M
Q2 25
$153.2M
$158.6M
Q1 25
$142.9M
$150.9M
Q4 24
$148.6M
Q3 24
$144.7M
$210.6M
Q2 24
$156.9M
$269.8M
Q1 24
$152.5M
$287.1M
Total Debt
FRPH
FRPH
LAB
LAB
Q4 25
$192.6M
Q3 25
$185.3M
Q2 25
$180.4M
Q1 25
$178.3M
Q4 24
$178.9M
Q3 24
$178.8M
$55.2M
Q2 24
$178.8M
$55.1M
Q1 24
$178.7M
$55.0M
Stockholders' Equity
FRPH
FRPH
LAB
LAB
Q4 25
$428.5M
Q3 25
$427.7M
$399.7M
Q2 25
$426.7M
$424.5M
Q1 25
$425.2M
$454.6M
Q4 24
$423.1M
Q3 24
$420.9M
$489.3M
Q2 24
$419.1M
$510.3M
Q1 24
$416.1M
$577.3M
Total Assets
FRPH
FRPH
LAB
LAB
Q4 25
$735.1M
Q3 25
$731.3M
$539.6M
Q2 25
$722.8M
$557.0M
Q1 25
$717.1M
$579.6M
Q4 24
$728.5M
Q3 24
$726.9M
$681.5M
Q2 24
$711.9M
$708.7M
Q1 24
$705.7M
$777.7M
Debt / Equity
FRPH
FRPH
LAB
LAB
Q4 25
0.45×
Q3 25
0.43×
Q2 25
0.42×
Q1 25
0.42×
Q4 24
0.42×
Q3 24
0.42×
0.11×
Q2 24
0.43×
0.11×
Q1 24
0.43×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRPH
FRPH
LAB
LAB
Operating Cash FlowLast quarter
$29.7M
$-22.2M
Free Cash FlowOCF − Capex
$-21.5M
$-23.1M
FCF MarginFCF / Revenue
-196.6%
-118.1%
Capex IntensityCapex / Revenue
468.5%
4.5%
Cash ConversionOCF / Net Profit
213.50×
TTM Free Cash FlowTrailing 4 quarters
$-34.4M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRPH
FRPH
LAB
LAB
Q4 25
$29.7M
Q3 25
$8.1M
$-22.2M
Q2 25
$8.7M
$-20.7M
Q1 25
$4.5M
$-30.3M
Q4 24
$29.0M
Q3 24
$6.3M
$-27.9M
Q2 24
$12.2M
$-39.0M
Q1 24
$2.9M
$-62.5M
Free Cash Flow
FRPH
FRPH
LAB
LAB
Q4 25
$-21.5M
Q3 25
$-16.9M
$-23.1M
Q2 25
$2.6M
$-22.6M
Q1 25
$1.4M
$-35.3M
Q4 24
$-22.2M
Q3 24
$-28.2M
$-30.1M
Q2 24
$5.9M
$-41.0M
Q1 24
$-3.3M
$-63.3M
FCF Margin
FRPH
FRPH
LAB
LAB
Q4 25
-196.6%
Q3 25
-157.0%
-118.1%
Q2 25
24.0%
-103.6%
Q1 25
13.6%
-86.6%
Q4 24
-210.9%
Q3 24
-265.7%
-136.4%
Q2 24
56.0%
-182.2%
Q1 24
-32.6%
-138.9%
Capex Intensity
FRPH
FRPH
LAB
LAB
Q4 25
468.5%
Q3 25
232.0%
4.5%
Q2 25
55.9%
8.7%
Q1 25
30.1%
12.4%
Q4 24
486.1%
Q3 24
325.1%
10.2%
Q2 24
60.3%
8.6%
Q1 24
61.2%
1.7%
Cash Conversion
FRPH
FRPH
LAB
LAB
Q4 25
213.50×
Q3 25
12.21×
Q2 25
15.00×
Q1 25
2.63×
Q4 24
17.18×
Q3 24
4.65×
Q2 24
5.96×
Q1 24
2.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRPH
FRPH

Other$5.6M51%
Multifamily Segment$5.3M49%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons